{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:41:40Z","timestamp":1791214900950,"version":"4.1.0"},"reference-count":40,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,5,26]],"date-time":"2011-05-26T00:00:00Z","timestamp":1306368000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2011,6]]},"abstract":"<jats:sec><jats:title>BACKGROUND AND PURPOSE<\/jats:title><jats:p>Antidepressants are one of the recommended treatments for neuropathic pain. However, their analgesic action remains unpredictable, and there are no selection criteria for clinical use. Better knowledge of their mechanism of action could help highlight differences underlying their unequal efficacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>EXPERIMENTAL APPROACH<\/jats:title><jats:p>We compared the activity of a tricyclic antidepressant (clomipramine) with selective 5\u2010HT and noradrenaline reuptake inhibitors (milnacipran and duloxetine) in streptozocin\u2010induced diabetic and chronic constriction nerve injury\u2010induced neuropathic rats, after repeated injections. We looked for an opioidergic mechanism in their action.<\/jats:p><\/jats:sec><jats:sec><jats:title>KEY RESULTS<\/jats:title><jats:p>Abolition of mechanical hyperalgesia was observed in mononeuropathic rats after five injections of clomipramine (5\u2003mg\u00b7kg<jats:sup>\u22121<\/jats:sup>, s.c.) and milnacipran (10 or 20\u2003mg\u00b7kg<jats:sup>\u22121<\/jats:sup>, i.p.) and in diabetic rats after clomipramine. An additional antinociceptive effect was obtained with five injections of duloxetine (3\u2003mg\u00b7kg<jats:sup>\u22121<\/jats:sup>, i.p.) in both models and milnacipran (10\u2003mg\u00b7kg<jats:sup>\u22121<\/jats:sup>, i.p.) in diabetic rats. These effects were observed with plasma antidepressant concentrations similar to those found in patients treated for neuropathic pain. Naloxone (1\u2003mg\u00b7kg<jats:sup>\u22121<\/jats:sup>, i.v.) only suppressed the anti\u2010hyperalgesic effects of clomipramine in both models of pain and of milnacipran in the traumatic model.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS AND IMPLICATIONS<\/jats:title><jats:p>The opioid system appears to be involved in the mechanism of action of antidepressants that only have an anti\u2010hyperalgesic effect but not in those that have a stronger (i.e. antinociceptive) effect. These differences between the antidepressants occurred whatever the aetiology of the neuropathy and, if confirmed in clinical trials, could be used to decide which antidepressant is administered to a patient with neuropathic pain.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1476-5381.2011.01297.x","type":"journal-article","created":{"date-parts":[[2011,3,4]],"date-time":"2011-03-04T07:48:03Z","timestamp":1299224883000},"page":"792-803","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Evidence for a differential opioidergic involvement in the analgesic effect of antidepressants: prediction for efficacy in animal models of neuropathic pain?"],"prefix":"10.1111","volume":"163","author":[{"given":"A\u2010S","family":"Wattiez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Libert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A\u2010M","family":"Privat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Loiodice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Fialip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Eschalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Courteix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,5,26]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(92)90152-2"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(88)90209-6"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2004.09.012"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410130209"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200923060-00006"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(00)01080-6"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1985.tb03182.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(94)90218-6"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2007.08.033"},{"key":"e_1_2_8_11_1","first-page":"1895","article-title":"[Analgesics of the morphine type (and their antagonists)]","volume":"40","author":"Eschalier A","year":"1990","journal-title":"Rev Prat"},{"key":"e_1_2_8_12_1","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0022-3565(25)24114-3","article-title":"Pharmacokinetic patterns of repeated administration of antidepressants in animals. I. Implications for antinociceptive action of clomipramine in mice","volume":"245","author":"Eschalier A","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_8_13_1","first-page":"907","article-title":"[Analgesics. Utilization principles and rules, posology of morphine and its derivatives]","volume":"50","author":"Eschalier A","year":"2000","journal-title":"Rev Prat"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2005.08.013"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.35.12.1309"},{"key":"e_1_2_8_16_1","first-page":"193","volume-title":"Pain 2010: An Updated Review, Refresher Course Syllabus","author":"Gilron I","year":"2010"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(84)90189-4"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.070656"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.12.002"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2006.02.001"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2004.01.005"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1159\/000115497"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2006.09.016"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(03)00270-2"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.052613"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2006.05.004"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/026988110201600311"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-002-1111-5"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(96)84628-4"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1213\/01.ANE.0000149546.97299.A2"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2007.08.001"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(87)90458-8"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(01)01308-5"},{"key":"e_1_2_8_34_1","first-page":"409","article-title":"A method for measurement of analgesic activity on inflamed tissue","volume":"111","author":"Randall LO","year":"1957","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(87)90548-X"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1990.tb03836.x"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2005.pto_96696601.x"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1213\/ane.0b013e318167889a"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neures.2009.04.010"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(98)00099-2"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(83)90201-4"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1476-5381.2011.01297.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1476-5381.2011.01297.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T06:21:35Z","timestamp":1740982895000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1476-5381.2011.01297.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,26]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["10.1111\/j.1476-5381.2011.01297.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01297.x","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,26]]},"assertion":[{"value":"2011-05-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}